Insider Selling: Liquidia Co. (NASDAQ:LQDA) Insider Sells 2,445 Shares of Stock

Liquidia Co. (NASDAQ:LQDA) insider Rajeev Saggar sold 2,445 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $13.00, for a total transaction of $31,785.00. Following the transaction, the insider now directly owns 267,943 shares of the company’s stock, valued at $3,483,259. The trade was a 0.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Rajeev Saggar also recently made the following trade(s):

• On Tuesday, January 14th, Rajeev Saggar sold 6,249 shares of Liquidia stock. The stock was sold at an average price of $11.78, for a total value of $73,613.22.

Liquidia Stock Up 3.2 %

Shares of NASDAQ:LQDA traded up $0.45 on Thursday, reaching $14.40. The company had a trading volume of 1,260,826 shares, compared to its average volume of 966,916. The stock has a market capitalization of $1.22 billion, a P/E ratio of -8.83 and a beta of 0.23. The stock has a 50-day moving average price of $11.47 and a 200 day moving average price of $11.06. Liquidia Co. has a twelve month low of $8.26 and a twelve month high of $16.99.

Institutional Investors Weigh In On Liquidia

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Profund Advisors LLC lifted its position in shares of Liquidia by 31.6% during the 2nd quarter. Profund Advisors LLC now owns 14,434 shares of the company’s stock worth $173,000 after purchasing an additional 3,466 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Liquidia during the second quarter valued at about $545,000. Squarepoint Ops LLC lifted its stake in shares of Liquidia by 53.4% in the second quarter. Squarepoint Ops LLC now owns 82,272 shares of the company’s stock valued at $987,000 after buying an additional 28,638 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Liquidia by 25.2% in the second quarter. The Manufacturers Life Insurance Company now owns 22,706 shares of the company’s stock valued at $272,000 after buying an additional 4,572 shares during the period. Finally, Bluefin Capital Management LLC acquired a new stake in Liquidia during the second quarter worth about $277,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

LQDA has been the topic of a number of research analyst reports. Needham & Company LLC reissued a “buy” rating and set a $19.00 price target on shares of Liquidia in a report on Thursday, January 9th. Scotiabank began coverage on Liquidia in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $29.00 price target on shares of Liquidia in a report on Thursday, November 14th. Wells Fargo & Company started coverage on Liquidia in a report on Friday, December 20th. They set an “overweight” rating and a $20.00 price objective for the company. Finally, Lifesci Capital assumed coverage on Liquidia in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 target price on the stock. One analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Liquidia currently has an average rating of “Buy” and a consensus price target of $25.38.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).